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  EVIDENCE-BASED ANSWER 
No studies clearly demonstrate the best initial treatment for Parkinson’s disease. Levodopa improves motor 
function in Parkinson’s disease; however, long-term use is associated with irreversible dyskinesias and motor 
fluctuations. Compared with placebo, selegiline improves the motor symptoms of Parkinson’s disease and 
allows a physician to delay the introduction of levodopa by 9 to 12 months (strength of recommendation [SOR]: 
A, based on randomized controlled trials). 
Dopamine agonists—alone or combined with levodopa—have fewer associated dyskinesias and other motor 
complications but produce lower scores on activities of daily living and Unified Parkinson’s Disease Rating 
Scale (UPDRS) when compared with levodopa alone (SOR: A, based on systematic reviews of randomized 
controlled trials). Drug choices should be based on each patient’s individual symptoms and response to 
medication (Table). 
 
TABLE 
Medications for Parkinson’s disease 
Medication 
Starting 
dose 
Usual 
daily 
dose 
Approx 
cost/mo 
Selegiline 
5 mg 
every 
morning 
5 mg 
every 
morning 
and at 
noon 
$29 for 
10 mg/d 
Carbidopa/levodopa 
25/100 
mg tab 
3 times 
daily 
25/100 
mg 3 
times 
daily 
$76 for 
75/300 
mg/d 
Pergolide 
0.05 
mg/d 
2–3 
mg/d 
divided 
3 times 
daily 
$223 for 
2 mg/d 
Pramipexole 
0.375 
mg/d 
divided 
3 times 
daily 
1.5–4.5 
mg/d 
divided 
3 times 
daily 
$177 for 
3 mg/d 
Ropinirole 
0.25 mg 
3 times 
daily 
3 mg 
divided 
3 times 
daily 
$185 for 
3 mg/d 
  EVIDENCE SUMMARY 
Five randomized controlled trials15 have shown improved motor function and activities of daily living with 
selegiline vs placebo in early Parkinson’s disease. Two of these trials1,2 found that selegiline delayed the need 
for levodopa for 9 to 12 months. 
One large randomized controlled trial showed no difference in disability scores and an increase in mortality at 
5.6 years when comparing selegiline combined with levodopa to levodopa alone.6 A re-analysis of this study, 
as well as subsequent studies, have not supported this conclusion and found no increase in mortality in 
patients with a history of selegiline use.7-10 
Two Cochrane reviews found that patients who tolerated the dopamine agonist bromocriptine—when 
administered alone or with levodopa—had delayed dyskinesias and motor complications compared with 
levodopa alone.11,12 There was no change in off-time with the combination.12 A large randomized controlled 
trial comparing bromocriptine with levodopa demonstrated that at 3 years, disability scores were lower in the 
patients initially assigned to bromocriptine, but the difference was no longer significant at 9 years.13 
The bromocriptine group in this trial showed a lower incidence of dyskinesias when data from all patient groups 
were combined. However, when moderate to severe cases were analyzed separately, there was no significant 
difference.13 There was no difference in mortality between patients initially treated with bromocriptine vs 
levodopa.13,14 
Studies of other dopamine agonists show results comparable with bromocriptine. Lisuride (not available in the 
US) with rescue levodopa vs levodopa alone had fewer motor complications at 4 years but lower UPDRS and 
activities of daily living scores.15 Another study comparing lisuride (with or without levodopa) vs levodopa alone 
found no difference in motor complications at 5 years.16 Studies with cabergoline, pramipexole, and 
pergolide—alone or combined with levodopa—vs levodopa alone showed a decrease in motor complications 
with the dopamine agonist but lower activities of daily living and UPDRS scores.17-19 
  RECOMMENDATIONS FROM OTHERS 
In 2002, the American Academy of Neurology published practice parameters for the initiation of treatment for 
Parkinson’s disease based on literature from 1966 to 1999. The authors concluded: 
• selegiline has mild symptomatic benefit and may be tried as initial therapy, but confers no 
neuroprotective effect 
• either levodopa or a dopamine agonist can be used for the initial treatment of symptomatic 
Parkinson’s disease 
• levodopa has a higher risk of dyskinesias than a dopamine agonist but superior motor benefits,20 
and is less likely to have other side effects (nausea, hallucinations, somnolence, and edema). 
CLINICAL COMMENTARY 
Family physicians play a key role in monitoring 
Parkinson’s 
 
Randy  Ward,  MD 
Medical College of Wisconsin,Milwaukee 
Parkinson’s disease has a profound impact on a patient’s physical and psychological 
wellbeing. Difficulties with movement, autonomic nervous system abnormalities, 
neuropsychiatric symptoms, and problems with medication effectiveness and side effects 
all occur throughout its course. Consultation with a neurologist skilled in this disorder can 
be quite helpful, particularly in younger patients or when the diagnosis is unclear. The 
family physician plays a key role in monitoring of the patient’s condition. Active 
management of symptoms (and comorbidities as they arise) is crucial in helping patients 
maintain their functional status and quality of life. 
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